AC Immune SA (NASDAQ: ACIU) stock jumped 23.81% on Wednesday to $3.12 against a previous-day closing price of $2.52. With 0.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 55170.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.1400 whereas the lowest price it dropped to was $2.9400. The 52-week range on ACIU shows that it touched its highest point at $8.14 and its lowest point at $2.06 during that stretch. It currently has a 1-year price target of $10.67. Beta for the stock currently stands at 0.72.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ACIU was up-trending over the past week, with a rise of 30.00%, but this was down by -2.19% over a month. Three-month performance dropped to -14.05% while six-month performance fell -30.51%. The stock lost -55.36% in the past year, while it has lost -36.97% so far this year. A look at the trailing 12-month EPS for ACIU yields -0.96 with Next year EPS estimates of -0.32. For the next quarter, that number is -0.24. This implies an EPS growth rate of -13.10% for this year and 67.00% for next year.
Float and Shares Shorts:
At present, 84.46 million ACIU shares are outstanding with a float of 40.05 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.44 million, which was 0.52% higher than short shares on Jun 14, 2022. In addition to Dr. Andrea Pfeifer Ph.D. as the firm’s Co-Founder, CEO & Director, Mr. Piergiorgio Donati serves as its Chief Technical Operations Officer.
Through their ownership of 18.79% of ACIU’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 3.68% of ACIU, in contrast to 14.20% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in ACIU with 8.89% of the stake, BVF Partners LP holds 7,428,379 shares worth 7,428,379. A second-largest stockholder of ACIU, Morgan Stanley & Co. LLC, holds 1,931,106 shares, controlling over 2.31% of the firm’s shares. Platinum Investment Management Lt is the third largest shareholder in ACIU, holding 1,059,462 shares or 1.27% stake. With a 1.05% stake in ACIU, the Handelsbanken Europa Småbolag is the largest stakeholder. A total of 874,186 shares are owned by the mutual fund manager. The FCP Medical – BioHealth, which owns about 0.40% of ACIU stock, is the second-largest Mutual Fund holder. It holds 336,892 shares valued at 1.02 million. iShares Biotechnology ETF holds 0.39% of the stake in ACIU, owning 328,454 shares worth 0.99 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ACIU since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ACIU analysts setting a high price target of $15.45 and a low target of $5.72, the average target price over the next 12 months is $10.22. Based on these targets, ACIU could surge 395.19% to reach the target high and rise by 83.33% to reach the target low. Reaching the average price target will result in a growth of 227.56% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ACIU will report FY 2022 earnings on 03/21/2023. Analysts have provided yearly estimates in a range of -$0.90 being high and -$1.00 being low. For ACIU, this leads to a yearly average estimate of -$0.95. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. AC Immune SA surprised analysts by $0.01 when it reported -$0.23 EPS against a consensus estimate of -$0.25. The surprise factor in the prior quarter was $0.00. Based on analyst estimates, the high estimate for the next quarter is -$0.20 and the low estimate is -$0.27. The average estimate for the next quarter is thus -$0.23.